Tesamorelin / Ipamorelin
Blend of Tesamorelin (GHRH analog) and Ipamorelin (GHRP), studied for GH-axis support, visceral fat, and recovery.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on Tesamorelin / Ipamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Combines a GHRH analog (Tesamorelin) with a GH secretagogue (Ipamorelin) for GH-axis stimulation; studied for body composition and recovery.
Tesamorelin mimics the body's growth hormone-releasing hormone to stimulate the pituitary, while ipamorelin mimics ghrelin to activate a separate receptor on the same gland, so together they trigger growth hormone release through two different pathways at once.
Reported side effects
The most commonly reported side effects from tesamorelin include injection-site reactions, joint pain, fluid retention, muscle aches, and possible glucose intolerance; ipamorelin may occasionally cause flushing or headache, but the combined side-effect profile of the blend has not been studied in humans.
Who should avoid it
People who are pregnant, have glucose intolerance or diabetes risk, or are not operating in a research context should avoid this blend, and anyone considering it should consult a qualified clinician first.
What gets monitored
Blood glucose monitoring is implied for anyone with glucose issues (GH lowers insulin sensitivity); a current Certificate of Analysis (COA) for the exact batch is recommended before use. An at-home blood test (SiPhox Health) is listed as a companion supply. [Source: peptidedosingprotocols.com]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesamorelin / Ipamorelin or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg (separate vials); or blend draws of 10-40 units/day depending on vial ratio (5/5 vial example: up to 667 mcg tesamorelin + 667 mcg ipamorelin at 40 units) | Once daily subcutaneousStandard: 8-12 weeks on, 4-8 weeks off; Extended: 12-16 weeks on, 4-8 weeks off; typical cycle 8-16 weeks | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
- Once daily subcutaneousStandard: 8-12 weeks on, 4-8 weeks off; Extended: 12-16 weeks on, 4-8 weeks off; typical cycle 8-16 weeks
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com]
- Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming the stream down the inside vial wall; swirl gently (do not shake) until fully dissolved. Inspect: solution should be clear; discard if cloudy or full of particles. Label with ratio, date, and concentration. Refrigerate at 2-8°C (35.6-46.4°F), protected from light. 10/3 vial yields ~4.33 mg/mL total (3.33 mg/mL tesamorelin + 1.0 mg/mL ipamorelin); 5/5 vial yields ~3.33 mg/mL total (1.67 mg/mL each). Do not freeze reconstituted solution.
Common questions
What is the tesamorelin and ipamorelin blend?
It is a combination of two growth hormone compounds. Tesamorelin is a GHRH analog and ipamorelin is a ghrelin-mimetic GH secretagogue. Together they target two different receptors that feed the same growth hormone pulse. The blend is sold for research use only and is not FDA-approved as a combination product.
What is the tesamorelin ipamorelin blend dosage per day?
Common research-planning structures use one subcutaneous dose per day with gradual titration. For reference, tesamorelin's FDA label dose alone is 2 mg/day (or 1.28 mg/day for the EGRIFTA WR formulation), and ipamorelin has been studied around 100–300 mcg per dose. This is not a dosing recommendation. Use the calculator for your exact vial.
What is the difference between the 10/3 and 5/5 blend?
The 10/3 vial holds 10 mg tesamorelin and 3 mg ipamorelin (13 mg total), so it is GHRH-dominant. The 5/5 vial holds 5 mg of each (10 mg total) for a balanced 1:1 ratio. The ratio changes how much of each compound is in every draw, so reconstitute and measure with your specific ratio in mind.
How do you reconstitute the tesamorelin ipamorelin blend?
Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming down the wall, then swirl gently until clear. A 10/3 vial becomes about 4.33 mg/mL total; a 5/5 vial becomes about 3.33 mg/mL total.
Open the reconstitution calculator →Can you take tesamorelin and ipamorelin together?
They are commonly combined in research planning because they act on two different GH pathways, and GHRH-plus-secretagogue pairings have amplified GH pulses in human secretagogue studies. However, no human trial has tested this specific blend, so the combined safety and effect profile is not established. This is educational information, not medical advice.
When is the blend usually taken?
Once-daily evening or bedtime dosing is the most common structure, chosen to track the body's natural nighttime GH release. Some separate-vial users place ipamorelin earlier in the day. Timing is a planning convention here, not a medical instruction.
How long is a typical cycle?
Research-planning cycles commonly run 8–16 weeks followed by 4–8 weeks off, a convention used to limit receptor desensitization. There is no established cycle length for the blend specifically.
Is the tesamorelin ipamorelin blend FDA-approved?
No. As of June 2026, tesamorelin is FDA-approved only for HIV-associated lipodystrophy (sold as EGRIFTA WR and EGRIFTA SV), ipamorelin is not FDA-approved, and the blend is not FDA-approved. It is sold for research use only.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for Tesamorelin / Ipamorelin as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
Blend of retatrutide (triple incretin agonist) and MOTS-c (mitochondrial-derived peptide), studied for metabolic and body-composition research.
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.